Trial Profile
RIAltO: A Randomised Investigation of Alternative Ofatumumab-containing regimens in less fit patients with CLL
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary) ; Bendamustine; Chlorambucil
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms RIAltO
- 12 Dec 2023 Results of deep immune profiling identifying novel T-Cell subpopulations that influence specific clinical outcomes in chronic lymphocytic leukaemia, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results assessing the immunomodulatory effects of chemo-immunotherapy plus idelalisib in chronic lymphocytic leukaemia patients, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 17 Jun 2018 Updated results of an ad hoc analysis (n=145) presented at the 23rd Congress of the European Haematology Association